A 32-year-old woman from Mumbai presents with a 6-month history of progressive muscle weakness, ptosis, and diplopia. Clinical examination suggests myasthenia gravis (MG). Serology for anti-acetylcholine receptor (AChR) antibodies is negative, but clinical suspicion remains high. The neurologist suspects seronegative MG and wants to confirm the diagnosis. Which molecular technique should be used next to detect anti-muscle-specific kinase (MuSK) antibodies and differentiate this subset?

Explanation

## Clinical Context Seronegative myasthenia gravis (MG) accounts for ~10–15% of MG cases. Approximately 40% of seronegative patients harbour antibodies against muscle-specific kinase (MuSK), a key component of the neuromuscular junction. Detecting anti-MuSK antibodies confirms the diagnosis and guides immunotherapy. ## Why ELISA/Immunoprecipitation is Correct **Key Point:** ELISA and immunoprecipitation are the gold-standard techniques for detecting **antibodies in patient serum** against specific protein antigens (MuSK). - **ELISA** (Enzyme-Linked Immunosorbent Assay): Recombinant MuSK protein is coated on a plate; patient serum is added; anti-MuSK IgG binds; detection via enzyme-conjugated secondary antibody. Quantitative, high throughput, clinically available. - **Immunoprecipitation**: Patient serum is incubated with recombinant MuSK; immune complexes are pulled down; detected by Western blot or mass spectrometry. More sensitive for low-titre antibodies. Both detect **antibodies** (the pathogenic factor), not the MuSK gene itself. **High-Yield:** Anti-MuSK seronegative MG has a distinct phenotype: ocular symptoms predominate, less thymic involvement, and better response to rituximab (anti-B cell therapy). ## Blotting & PCR Techniques: Why They Are Wrong Here | Technique | Detects | Use Case | Why Wrong for Anti-MuSK? | |-----------|---------|----------|-------------------------| | **Southern Blot** | DNA fragments via restriction enzyme digestion + hybridization | Gene deletions, rearrangements, copy number | Detects *MuSK gene*, not antibodies; not relevant for diagnosis | | **Western Blot** | Proteins in tissue/serum via antibody probes | Protein expression, post-translational modifications | Can detect MuSK *protein* in lysates, but not patient *antibodies* against it; labour-intensive | | **PCR** | DNA/RNA sequences via enzymatic amplification | Gene mutations, pathogen detection, copy number | Amplifies *MuSK gene* from patient cells; does not detect serum antibodies; irrelevant for MG diagnosis | **Clinical Pearl:** Western blot *could* theoretically be used if serum is applied as the "antibody probe" against recombinant MuSK protein (i.e., reverse immunology), but this is non-standard and less sensitive than ELISA or immunoprecipitation. ## Diagnostic Algorithm ```mermaid flowchart TD A[Clinical suspicion of MG]:::outcome --> B[Anti-AChR serology]:::action B --> C{Positive?}:::decision C -->|Yes| D[Confirm AChR-MG]:::outcome C -->|No| E[Seronegative MG]:::outcome E --> F[Anti-MuSK serology<br/>ELISA or IP]:::action F --> G{Anti-MuSK+?}:::decision G -->|Yes| H[MuSK-MG confirmed]:::outcome G -->|No| I[Double-seronegative MG<br/>consider LRP4 antibodies]:::outcome ``` **Mnemonic:** **ELISA for Antibodies, PCR for DNA/RNA, Blots for Proteins in Lysates** — remember the *target* (serum antibody vs. gene vs. tissue protein).